Robert W. Baird analyst Jeff Johnson reiterated a Buy rating on Henry Schein (HSIC – Research Report) on November 5 and set a price ...

Henry Schein (HSIC – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Michael ...

"We believe we continued to steadily gain market share in our dental and medical distribution businesses following last year's cyber incident. Our dental equipment business is showing ongoing ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $79.5, a high estimate of $82.00, ...

Dental supply company Henry Schein reported total net sales of $3.2 billion during the third quarter of 2024, according to a Nov. 5 financial report. Here are eight things to know: 1. Third-quarter ...

Sales at its dental unit, which supplies implants and tooth-whitening products, among other items, came in at $1.85 billion, below expectations of $1.89 billion. Henry Schein's selling, general and ...

The dental supplies firm raised the lower end of its 2024 adjusted earnings projection, and now anticipates a range between $4.74 and $4.82 a share, compared with the prior $4.70-to-$4.82 a share ...

Analysts' ratings for Henry Schein (NASDAQ ... is engaged in combining global dental and medical businesses and distributes consumable products, small equipment, laboratory products, and Vitamins.

Henry Schein is a Fortune 500 company and one of the global leaders in its industry, providing healthcare solutions, as well as the distribution of medical, dental, and veterinary supplies.